Synlogic

CAMBRIDGE, MA · Founded 2007 · Biotech · Acquired

Engineered gut bacteria (synthetic biotics) that produce therapeutic metabolites for treating metabolic and inflammatory diseases

Claim this profile

Follows are private to you and power your alerts

Updated · synlogictx.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Founded
2007
Latest Form D
$80M, Jun 2019
Total capital
$141M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$141M
4 Form D · last Jun 2019
88 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $141M1st Form D$1.5M2nd Form D$17.2M3rd Form D$41.8M4th Form D$80M
20112013201520172019FEDERAL ↑EQUITY ↓Cumulative $141M3rd Form D$41.8M4th Form D$80M

Latest events

  • Private capital raisedForm D · SEC · 4th filing$80M
  • Private capital raisedForm D · SEC · 3rd filing$41.8M
  • Private capital raisedForm D · SEC · 2nd filing$17.2M
  • Private capital raisedForm D · SEC · 1st filing$1.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • ANKIT MAHADEVIAExecutive Officer, DirectorNamed in SEC Form D filings
  • Aoife BrennanExecutive OfficerNamed in SEC Form D filings
  • Bharatt ChowriraExecutive OfficerNamed in SEC Form D filings
  • Chau KhuongDirectorNamed in SEC Form D filings
  • DANIEL GEFFKENExecutive OfficerNamed in SEC Form D filings
  • Ed MathersDirectorNamed in SEC Form D filings
Show all 17 people
  • Edward MathersDirectorNamed in SEC Form D filings
  • Jose Carlos Gutierrez-RamosExecutive Officer, DirectorNamed in SEC Form D filings
  • LEWIS GEFFENExecutive OfficerNamed in SEC Form D filings
  • Michael PowellDirectorNamed in SEC Form D filings
  • Michael SheahanExecutive OfficerNamed in SEC Form D filings
  • Nick LeschlyDirectorNamed in SEC Form D filings
  • Patricia HurterDirectorNamed in SEC Form D filings
  • Paul MillerExecutive OfficerNamed in SEC Form D filings
  • Peter BarrettDirectorNamed in SEC Form D filings
  • Richard P. SheaDirectorNamed in SEC Form D filings
  • Todd ShegogExecutive OfficerNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Clene Nanomedicine, Inc.Similar federal contract value in Biotech · null in contracts
  • TNA Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
  • XGENOMES CORP.Similar federal contract value in Biotech · null in contracts
  • Akero TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Pionyr ImmunotherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Nkarta, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .